Relevant bibliographies by topics / Prognostic markers

Academic literature on the topic 'Prognostic markers'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Contents

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Prognostic markers.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Prognostic markers"

1

Kovaleva, Olga V., Madina A. Rashidova, Daria V. Samoilova, Polina A. Podlesnaya, Rasul M. Tabiev, Valeria V. Mochalnikova, and Alexei Gratchev. "CHID1 Is a Novel Prognostic Marker of Non-Small Cell Lung Cancer." International Journal of Molecular Sciences 22, no. 1 (January 5, 2021): 450. http://dx.doi.org/10.3390/ijms22010450.

Full text
Abstract:
There is an urgent need for identification of new prognostic markers and therapeutic targets for non-small cell lung cancer (NSCLC). In this study, we evaluated immune cells markers in 100 NSCLC specimens. Immunohistochemical analysis revealed no prognostic value for the markers studied, except CD163 and CD206. At the same time, macrophage markers iNOS and CHID1 were found to be expressed in tumor cells and associated with prognosis. We showed that high iNOS expression is a marker of favorable prognosis for squamous cell lung carcinoma (SCC), and NSCLC in general. Similarly, high CHID1 expression is a marker of good prognosis in adenocarcinoma and in NSCLC in general. Analysis of prognostic significance of a high CHID1/iNOS expression combination showed favorable prognosis with 20 months overall survival of patients from the low CHID1/iNOS expression group. For the first time, we demonstrated that CHID1 can be expressed by NSCLC cells and its high expression is a marker of good prognosis for adenocarcinoma and NSCLC in general. At the same time, high expression of iNOS in tumor cells is a marker of good prognosis in SCC. When used in combination, CHID1 and iNOS show a very good prognostic capacity for NSCLC. We suggest that in the case of lung cancer, tumor-associated macrophages are likely ineffective as a therapeutic target. At the same time, macrophage markers expressed by tumor cells may be considered as targets for anti-tumor therapy or, as in the case of CHID1, as potential anti-tumor agents.
APA, Harvard, Vancouver, ISO, and other styles
2

Taha, Anas, Stephanie Taha-Mehlitz, Stephanie Petzold, Sergey L. Achinovich, Dmitry Zinovkin, Bassey Enodien, Md Zahidul I. Pranjol, and Eldar A. Nadyrov. "Prognostic Value of Immunohistochemical Markers for Locally Advanced Rectal Cancer." Molecules 27, no. 3 (January 18, 2022): 596. http://dx.doi.org/10.3390/molecules27030596.

Full text
Abstract:
The aim of this study is to reveal the potential roles of apoptosis markers (Bcl2 and p53), proliferation markers (Ki-67 and CyclD1), and the neuroendocrine marker Chromogranin A as markers for the radioresistance of rectal cancer. Statistically significant differences were found in the expression of p53, Ki-67, and Chromogranin A in groups of patients with and without a favorable prognosis after radiotherapy. The survival analysis revealed that the marker of neuroendocrine differentiation, Chromogranin A, also demonstrated a high prognostic significance, indicating a poor prognosis. Markers of proliferation and apoptosis had no prognostic value for patients who received preoperative radiotherapy. Higher Chromogranin A values were predictors of poor prognosis. The results obtained from studying the Chromogranin A expression suggest that the secretion of biologically active substances by neuroendocrine cells causes an increase in tumor aggressiveness.
APA, Harvard, Vancouver, ISO, and other styles
3

Elias, Jules M. "The Prognosis of Prognostic Markers. Quo Vadis?" Journal of Histotechnology 19, no. 1 (March 1996): 7–8. http://dx.doi.org/10.1179/his.1996.19.1.7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Veryaskina, Yuliya Andreevna, Sergei Evgenievich Titov, Igor Borisovich Kovynev, Tatiana Ivanovna Pospelova, and Igor Fyodorovich Zhimulev. "Prognostic Markers of Myelodysplastic Syndromes." Medicina 56, no. 8 (July 27, 2020): 376. http://dx.doi.org/10.3390/medicina56080376.

Full text
Abstract:
Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid leukemia. In theory, from clonal hematopoiesis of indeterminate potential to hematologic malignancies, there is a complex interplay between genetic and epigenetic factors, including miRNA. In practice, karyotype analysis assigns patients to different prognostic groups, and mutations are often associated with a particular disease phenotype. Among myeloproliferative disorders, secondary MDS is a group of special entities with a typical spectrum of genetic mutations and cytogenetic rearrangements resembling those in de novo MDS. This overview analyzes the present prognostic systems of MDS and the most recent efforts in the search for genetic and epigenetic markers for the diagnosis and prognosis of MDS.
APA, Harvard, Vancouver, ISO, and other styles
5

Chen, LangXiong, XiaoSong He, ShiJiang Yi, GuanCheng Liu, Yi Liu, and YueFu Ling. "Six Glycolysis-Related Genes as Prognostic Risk Markers Can Predict the Prognosis of Patients with Head and Neck Squamous Cell Carcinoma." BioMed Research International 2021 (February 10, 2021): 1–13. http://dx.doi.org/10.1155/2021/8824195.

Full text
Abstract:
Objective. Head and neck squamous cell carcinoma (HNSCC) is one of the worst-prognosis malignant tumors. This study used bioinformatic analysis of the transcriptome sequencing data of HNSCC and the patients’ survival and clinical data to construct a prediction signature of glycolysis-related genes as the prognostic risk markers. Methods. Gene expression profile data about HNSCC tissues ( n = 498 ) and normal tissues in the head and neck ( n = 44 ) were got from The Cancer Genome Atlas (TCGA), as well as patients’ survival and clinical data. Then, we obtained core genes; their expression in head and neck squamous cell carcinoma tissues is significantly different from that in normal head and neck tissues. The predicted glycolysis-related genes are screened through univariate Cox regression analysis, and then, the prognostic risk markers were constructed through further correction of multivariate Cox regression analysis. The Kaplan-Meier curve and receiver operating characteristic curve are used to analyze the potential value of these risk markers in diagnosis and prognosis. We also evaluated that the glycolysis-related prognostic risk markers composed of 6 oncogenes are correlated with clinical features, such as age, gender, grade, and clinical stage of the tumor, by univariate and multivariate Cox regression analyses. Results. Differentially expressed glycolytic genes in HNSCC tissues and normal head and neck tissues were screened from TCGA databases using the bioinformatic method. We confirmed a set of six glycolytic genes that were significantly associated with OS in the test series. According to our analysis, the prognostic risk markers composed of HPRT1, STC2, PLCB3, GPR87, PYGL, and SLC5A12 may be an independent risk factor for the prognosis of HNSCC. Conclusions. Through this analysis, we constructed new prognostic risk markers related to glycolysis as a prognostic risk marker for patients with HNSCC and provided new ideas and molecular targets for the research and individualized treatment of HNSCC.
APA, Harvard, Vancouver, ISO, and other styles
6

Alieva, A. M., A. V. Sozykin, N. V. Teplova, E. V. Reznik, D. V. Izimarieva, N. A. Novikova, I. V. Lozovsky, Е. E. Averin, R. K. Valiev, and I. G. Nikitin. "Tenascin-C as a cardiovascular marker." Russian Journal of Cardiology 27, no. 8 (September 3, 2022): 5150. http://dx.doi.org/10.15829/1560-4071-2022-5150.

Full text
Abstract:
Novel biological markers, such as fibrosis marker galectin-3, peptide hormone adrenomedullin, soluble ST2, chemokine CX3CL1, surrogate marker of vasopressin, and others, are every year one step closer to being introduced into health practice. Over the past decades, significant progress has been made in the study of cardiovascular biomarkers. A key moment was the introduction of deter mining the concentration of natriuretic peptides used as markers for the diagnostic and prognostic evaluation of patients with heart failure. Currently, in order to search for novel markers for early diagnosis and risk stratification, studies have been conducted on the analysis of promising inflammatory marker tenascin-C (TNC) in cardiovascular patients. Data have been obtained that allow us to consider TNC as a tool for risk stratification and assessment of cardiovascular disease prognosis. The combination of TNC with other biological markers, in particular brain natriuretic peptide, may improve prognostic power. Nevertheless, serial testing to assess the prognosis and effectiveness of ongoing treatment, including in the conditions of a multimarker model, requires further research.
APA, Harvard, Vancouver, ISO, and other styles
7

Labussiere, Marianne, Xiao-Wei Wang, Ahmed Idbaih, François Ducray, and Marc Sanson. "Prognostic markers in gliomas." Future Oncology 6, no. 5 (May 2010): 733–39. http://dx.doi.org/10.2217/fon.10.25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Perkins, Geraldine, Pierre Laurent-Puig, and Julien Taieb. "Ampullary carcinoma prognostic markers." Oncotarget 10, no. 44 (July 16, 2019): 4509–10. http://dx.doi.org/10.18632/oncotarget.27067.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bakhshi, Sameer, and Venkatraman Radhakrishnan. "Prognostic markers in osteosarcoma." Expert Review of Anticancer Therapy 10, no. 2 (February 2010): 271–87. http://dx.doi.org/10.1586/era.09.186.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ross, Jeffrey S., Christine E. Sheehan, Hugh AG Fisher, Ronald A. Kauffman, Eric M. Dolen, and Bhaskar VS Kallakury. "Prognostic markers inprostate cancer." Expert Review of Molecular Diagnostics 2, no. 2 (March 2002): 129–42. http://dx.doi.org/10.1586/14737159.2.2.129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Prognostic markers"

1

Oguejiofor, Kenneth Kenechukwu. "Prognostic markers in oropharyngeal cancers." Thesis, University of Manchester, 2016. https://www.research.manchester.ac.uk/portal/en/theses/prognostic-markers-in-oropharyngeal-cancers(fda96224-657d-4049-ae6c-50db33a5388a).html.

Full text
Abstract:
Introduction: Human papillomavirus (HPV) is changing the prevalence, survival and treatment paradigms in oropharyngeal squamous cell carcinoma (OPSCC). Improved survival of patients with HPV positive compared to HPV negative OPSCC has led to trials of treatment de-escalation. Current HPV detection methods are imprecise, therefore standardised assessment of transcriptionally active HPV in OPSCC is required. Furthermore, the differences in immune characteristics and/or the hypoxia response/effects could explain observed differences in prognosis between HPV positive and negative OPSCC. Rigorous HPV detection and subsequent biomarker evaluation should provide additional information required before introduction of treatment de-escalation in broad patient groupings. Methods: The study cohort was 218 patients with OPSCC who received radiotherapy with curative intent. HPV status was determined on pre-treatment, formalin-fixed paraffin-embedded blocks using: 1) polymerase chain reaction (PCR); 2) in-situ hybridisation (ISH) and 3) immuno-histochemistry (IHC). QuantiGene multiplex assay was designed to detect mRNA of reference sequences of the common high-risk HPV types (16, 18, 33, 35, 45, 52 and 58). HPV detection methods were compared with mRNA quantification. Multimarker IHC of immune cell markers using chromogenic and fluorescent staining was performed, analysed and compared with single marker IHC using automated multispectral image analysis. A validated multiplex IHC method was used for a) chromogenic (CD3, CD4, CD8, and FoxP3) and b) fluorescent (CD8, CD68 and PD1/PD-L1) evaluation in tumour and stroma compartments. Single marker IHC was used to investigate tumour hypoxia markers (HIF-1α and CA-IX) in HPV positive and negative OPSCC. Results: p16 IHC and ISH were the most sensitive and specific, respectively, for classifying HPV status. The combination of the three tests had the highest positive/negative predictive values compared with QuantiGene mRNA detection. Multiplex validation showed that, for serial sections up to 6 μm apart, there were highly significant correlations (P<0.0001) between single and multiplex counts for both chromogenic and fluorescent IHC. Overall there was less variation in cell counts with fluorescent staining when compared to chromogenic staining. Multiplex IHC of TILs in HPV positive and negative OPSCC showed higher infiltration in both tumour and stromal areas of CD3+CD4+ and CD3+CD8+ T cells but not CD4+FoxP3 Tregs in HPV positive compared with HPV negative OPSCC. Only CD3+CD8+ stromal and not tumour area infiltration was associated with increased survival (P=0.02). PD-L1 expression was higher in HPV negative OPSCC and this was related to macrophage (CD68) expression of PD-L1. In HPV negative tumours infiltration with CD68+PD-L1 was associated with a good prognosis. HPV negative patients had higher expression of HIF-1α but not CA-IX. High expression of both markers was associated with a poor prognosis irrespective of HPV status. Conclusions: There are other prognostic factors operating in the larger subdivision of HPV positive and negative OPSCC. Precise HPV detection and inclusion of other prognostic factors is required before treatment de-escalation is used. Expression of immune inhibitory factors (PD1/PD-L1) alone without contextualisation with immune cell density is insufficient for patient prognostication and potential selection for therapy using immune checkpoint inhibitors. Hypoxia modification of radiotherapy should be explored in both HPV positive and negative OPSCC.
APA, Harvard, Vancouver, ISO, and other styles
2

Blonski, Katharina. "Glycoconjugates as prognostic markers in ovarian cancer." [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=975965115.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Salih, Tamir. "Prognostic and predictive markers in oesophageal cancer." Thesis, University of Leeds, 2015. http://etheses.whiterose.ac.uk/15196/.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Douglas, Catriona Mairi. "Prognostic markers in head and neck cancer." Thesis, University of Manchester, 2011. http://www.manchester.ac.uk/escholar/uk-ac-man-scw:130436.

Full text
Abstract:
Purpose: The management of head and neck squamous cell carcinoma (HNSCC) is complex and often involves multimodality treatment. Currently, most management decisions are based on clinical parameters with little appreciation of patient differences in underlying tumour biology. The identification of biomarkers that predict response to radiotherapy would be clinically useful in determining optimal management. The purpose of the thesis was to investigate potential biomarkers that might predict radiotherapy outcome in patients with HNSCC. Aims: 1) To investigate the hypoxia-associated biomarkers carbonic anhydrase 9 (CA9) and hypoxia-inducible factor -1α (HIF-1α) in patients with early glottis cancer who underwent radiotherapy as their primary mode of treatment, furthermore to investigate the role of accelerated hypofractionated radiotherapy in the management of T2 glottic cancer. 2) To investigate markers of hypoxia (CA9 and HIF-1α) and viral infection in oropharyngeal cancer, and in particular to test for an association between hypoxia markers and viral infection. 3) To investigate HIF-1 and CA9 in a series of patients undergoing surgery as their primary mode of treatment to explore whether they are associated specifically with radioresponsiveness or a general poor prognosis. Results: 1) Adverse prognostic factors for locoregional control were low pre-treatment haemoglobin (Hb; p = 0.010), advancing T stage (p = 0.001) and high CA9 expression (p = 0.032). Low Hb and high CA9 expression were independent factors on multivariate analysis; and combined predicted locoregional recurrence with an odds ratio of 8.0 (95% CI: 2.7-23.9), or either/or with an odds ratio of 3.3 (95% CI 1.5-7.1). In the subset of T2 patients, five-year locoregional control following radiotherapy was 82% and cancer specific survival was 90%. Serious morbidity occurred in 1.8% of patients. T stage subdivided by vocal cord movement was significant for local control. 2) Features associated with a poor locoregional control were older age (p=0.002), tongue base subsite (p=0.002), heavy alcohol use (p=0.004), heavy smoker (p=0.0002), low Hb level (p=0.001), advancing T (p=<0.0001), N (p=0.001) and AJC (p=0.001) stage, high CA9 expression (p=0.020) and high HIF-1α expression (p<0.0001). In multivariate analysis T stage (p=0.003) and high HIF-1α expression (p=0.001) remained significant. 3) Extracapsular spread was significantly associated with poor cancer specific survival (p=0.022). No other patient variables were associated with outcome. HIF-1α expression was significantly associated with poorly differentiated tumour (p=0.019) and the tumour having a cohesive front (p=0.026). Conclusion: 1) Hb and CA9 have potential to be used together as a biomarker to identify glottis cancer patients with a high probability of a poor outcome following radiotherapy, furthermore, vocal cord movement should be taken into consideration when managing glottis cancer. 2) As it does not appear to be influenced by HPV status, HIF-1α warrants further investigation as a biomarker in oropharyngeal patients treated with primary radiotherapy. 3) As HIF-1α and CA9 had no prognostic significance in patients undergoing surgery, they should be explored further as markers to help guide management decisions in patients with HNSCC.
APA, Harvard, Vancouver, ISO, and other styles
5

Laird, Alexander. "Molecular prognostic markers in renal cell carcinoma." Thesis, University of Edinburgh, 2015. http://hdl.handle.net/1842/17873.

Full text
Abstract:
Renal cell carcinoma (RCC) is the most deadly of urological malignancies. While metastatic disease affects one third of patients at diagnosis, a further third of patients who undergo extirpative surgery with curative intent subsequently develop metastatic disease. Inconsistency in the clinical course ensures predicting subsequent metastasis is notoriously difficult, despite the routine use of prognostic clinico-pathological parameters in risk stratification. With greater understanding of pathways involved in disease pathogenesis, a number of biomarkers have been proposed to be of prognostic significance; however there are currently no molecular prognostic markers in clinical use. Genetic intra-tumoural heterogeneity (genetic ITH) has been described in clear cell RCC (ccRCC) and may limit the clinical translation of biomarkers. There has been no assessment of ITH at other molecular levels. The aim of this work was to define and compare proteomic, transcriptomic and DNA methylation ITH in ccRCC, and identify potential prognostic biomarkers. Using reverse phase protein arrays to study protein expression in multiple spatially separate regions of primary and metastatic ccRCC, proteomic ITH was demonstrated for the first time. Interestingly there was no significant difference in proteomic ITH in metastatic ccRCC tumour deposits compared to primary tumours. However, on analysis of differential protein expression between primary and metastatic ccRCC tissue using a tissue microarray and automated analysis of immunofluorescence, there was significantly greater expression of Ki67, p53, VEGFR1, SLUG and SNAIL in the metastases compared to the primary tumours. Subsequent profiling of gene expression and DNA methylation in multiple areas of the same primary tumours confirmed transcriptomic and methylomic ITH. On comparison of this multimolecular ITH, significantly greater proteomic ITH was seen compared to gene expression and DNA promoter methylation heterogeneity. Recent evidence suggests DNA methylation may be prognostically important in RCC and given the lower methylomic ITH in ccRCC, the identification of prognostic DNA methylation changes in ccRCC were pursued using the Infinium HumanMethylation450K Beadchip. Following development of an analysis pipeline, identification and validation of prognostic differentially methylated regions (DMR) was performed on an experimental cohort and published dataset respectively. Five DMRs, which were associated with disease recurrence in ccRCC, were identified. NEFM gene promoter methylation was the only DMR associated with cancer specific survival, independent of TNM stage and nuclear grade on multivariate analysis, which was confirmed on a third independent published dataset. This thesis therefore demonstrates multi-molecular ITH in ccRCC for the first time. Despite this, NEFM promoter methylation may be a useful independent prognostic marker of cancer specific survival.
APA, Harvard, Vancouver, ISO, and other styles
6

Sevov, Marie. "RNA-based Prognostic Markers in Chronic Lymphocytic Leukemia." Doctoral thesis, Uppsala universitet, Institutionen för genetik och patologi, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-133250.

Full text
Abstract:
Chronic lymphocytic leukemia (CLL) is a heterogeneous disease where a significant proportion of patients will develop an aggressive disease. Today, the mutational status of the immunoglobulin heavy variable (IGHV) genes is one of the strongest prognostic markers in CLL, where unmutated IGHV genes correlate with poor outcome. In addition, IGHV3-21 gene usage is associated with poor prognosis independent of mutational status. Recently, several genes were shown to be differently expressed between IGHV mutated and unmutated CLL and were suggested as prognostic markers. The aim of this thesis was to examine the applicability of these RNA-based prognostic markers in CLL. In papers I and II, the prognostic significance of LPL and TCL1A mRNA expression in CLL was investigated in 140 and 144 patients, respectively. High expression was found to be associated with inferior clinical outcome for both markers. However, CLL cases with mutated IGHV3-21 genes displayed low levels of LPL expression, indicating that LPL cannot identify this poor-risk patient group. In contrast, high TCL1A expression was detected in all IGHV3-21 cases. To elucidate the functionality of LPL in CLL, LPL lipase activity was measured in 33 cases. The lipase activity was found to be invariably low, implying an alternative function for LPL in CLL. In paper III, a comprehensive analysis of five RNA-based markers (LPL, TCL1A, ZAP70, CLLU1 and MCL1) was performed in 252 CLL patients. All RNA-based markers except MCL1 predicted clinical outcome, with LPL being the strongest. Moreover, LPL expression independently predicted overall survival when adjusted for established markers. All of the RNA-based markers added additional prognostic information to established markers, e.g. high LPL expression predicted an inferior outcome in patients with mutated IGHV genes or good-risk cytogenetics. For clinical application, over time stability of prognostic markers is crucial. In paper IV, the expression of LPL, TCL1A, ZAP70 and MCL1 was investigated in samples taken at diagnosis and at a follow-up of seven years in 104 CLL patients. LPL was found to be the most stable marker, displaying high correlation between the sequential samples, whereas ZAP70 and MCL1 varied significantly. TCL1A expression increased at follow-up, which may indicate disease progression as TCL1A promotes cell survival. In summary, this thesis highlights the applicability of RNA-based markers in CLL prognostication, both as single markers or in combination with established markers. In particular, LPL was shown to be the strongest RNA-based marker in terms of prognostic strength and stability.
APA, Harvard, Vancouver, ISO, and other styles
7

Whiteside, Michael C. R. "Genetic markers for prognostic prediction in colorectal cancer." Thesis, Queen's University Belfast, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.387972.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Kawesha, Anthony. "Prognostic molecular markers in resected ductal pancreatic carcinoma." Thesis, University of Birmingham, 2017. http://etheses.bham.ac.uk//id/eprint/7596/.

Full text
Abstract:
Previous studies of molecular prognostic markers following resection for exocrine pancreatic cancer have produced conflicting results. The aim of this study was to undertake a comprehensive analysis of potentially useful markers in a large multicentre patient population and compare these markers with standard pathological prognostic variables. Formalin fixed, paraffin-embedded specimens of pancreatic ductal adenocarcinoma were analysed from 157 patients (100 men and 57 women with a median [range] age of 60 [33-77] years) who had undergone pancreatectomy. Immunhistochemistry was used to detect expression of p16\(^{INK4}\), p53, p21\(^{WAF1}\), cyclin D1, c-erbB-2 and c-erbB-3. In a selected number of p53 positive and negative staining cases, mutational analysis was undertaken using DNA obtained from microdissected specimens. Mutations in codons 12 and 13 of the K-ras oncogene were detected by SSCP and sequencing following DNA extraction and amplification by PCR. The median [range] survival post-resection was 12.5 [3-83] months. Abnormalities of p16\(^{INK4}\), p53, p21\(^{WAF1}\), cyclin D1, c-erbB-2 and c-erbB-3 expression were found in 87%, 41%, 75%, 72%, 33% and 57% of cases, respectively. There was no significant correlation between expression of any of these markers and patient survival. K-ras mutations were found in 73 (75%) out of 97% cases with amplifiable DNA. The presence of K-ras mutation alone did not correlate with survival, but there were significant differences in survival according to the type of K-ras mutation (p=0.0007). Reduced survival was found in patients with GaT, cGT and GcT K-ras mutations compared to GtT, aGT and GaC mutations. In conclusion survival was associated with the type of K-ras mutation but not the expression of p16\(^{INK4}\), p53, p21\(^{WAF1}\), cyclinD1, c-erbB-2 and c-erbB3.
APA, Harvard, Vancouver, ISO, and other styles
9

Martins, Ana Teresa Pinto Teixeira. ""Prognostic Value Of Methilation Markers In Breast Cancer"." Master's thesis, Instituto de Ciências Biomédicas Abel Salazar, 2008. http://hdl.handle.net/10216/20022.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Bur, H. (Hamid). "Biological prognostic and predictive markers in Hodgkin lymphoma." Doctoral thesis, Oulun yliopisto, 2018. http://urn.fi/urn:isbn:9789526219455.

Full text
Abstract:
Abstract Hodgkin lymphoma (HL) is among a heterogeneous group of lymphomas. Over 80% of all patients can be cured with chemo- and radiotherapy. HL has become a model to study long-term effects of radio- and chemotherapy, because of the excellent prognosis. There are a significant number of patients who suffer or die because of the treatment-related long-term toxicity. The aim of this work was to discover new possible biological factors to predict poor prognosis and offer new aspects to individualize patient treatment in a convenient manner in HL. The retrospective study involved HL patients uniformly treated in 1997–2015. Immunohistochemistry was used to determine the expression of various biological markers, including oxidative stress markers 8-hydroxydeoxyguanosine (8-OHdG) and nitrotyrosine and the antioxidant enzymes manganese superoxide dismutase (MnSOD) as well as peroxiredoxins (Prx II, Prx III, Prx V, Prx VI) in HL patient samples. Using immunohistochemistry, we also evaluated expression of hypoxia-inducible factors (HIF-1α, HIF-2α), prolyl hydroxylase domain enzymes (PHD1, PHD2, PHD3), the epigenetic regulator lysine (K)-specific demethylase 4 (KDM4A, KDM4B, KDM4D) as well as sirtuins (SIRT1, SIRT4, SIRT6), the DNA-repair proteins Human Rap1 interacting factor 1 (Rif1) and O6-alkylguanine DNA alkyltransferase (MGMT) from representative classical Hodgkin lymphoma (cHL) patient samples. Low-level expression of 8-OHdG was associated with poorer relapse-free survival (RFS) in advanced-stage HL and a high extent of MnSOD predicted early relapse in the whole HL cohort. Strong expression of PHD1, KDM4B and KDM4D predicted dismal RFS in radiotherapy-treated cHL patients. The results also showed that strong expression of HIF-1α, SIRT6 and Rif1, and SIRT6 together with Rif1, were associated with prolonged RFS, especially in advanced-stage radiotherapy-treated cHL patients. In multivariate analysis, PHD1, MnSOD, 8-OHdG and Rif1 separately and together with SIRT6 were statistically significant predictors of RFS. The results reflect the significance of the studied biomarkers in HL, especially in radiotherapy-treated patients. This might be beneficial when individualizing treatment strategies, avoiding overtreatment and controlling long-term treatment-related toxicity. Further research, however, is needed to confirm these preliminary findings
Tiivistelmä Hodgkinin lymfooma (engl. HL) kuuluu heterogeeniseen imukudossyöpien eli lymfoomen ryhmään. Yli 80 % lymfoomapotilaista voidaan parantaa solunsalpaaja- ja sädehoidon avulla. Hyvän ennusteen takia HL- tutkimuksen tärkeä painopiste on säde- ja solunsalpaajahoidon pitkän ajan haittavaikutukset. Huomattava määrä potilaista kärsii tai jopa kuolee hoitoon liittyvistä pitkäaikaishaitoista johtuen. Tämän tutkimuksen tarkoituksena oli löytää uusia mahdollisia biologisia tekijöitä, jotka ennakoisivat taudin huonoa ennustetta ja samalla antaa uusia näkökulmia HL potilaiden hoidon yksilöllistämiseen. Tämä retrospektiivinen tutkimus käsitti vuosina 1997-2015 samanlaisesti hoidettuja Hodgkinin lymfooma -potilaita. Immunohistokemiallisilla värjäyksillä määritettiin biologisten merkkiaineiden, mukaan lukien oksidatiivisen stressin markkereiden 8- hydroksideoksiguanosiinin (8-OHdG) ja nitrotyrosiinin, sekä antioksidanttientsyymien mangaanisuperoksidi-dismutaasin (MnSOD) sekä peroksiredoksiinien (Prx II, Prx III, Prx V, Prx VI) ilmentymistä HL -potilasnäytteissä. Määrittelimme myös immunohistokemiallisilla värjäyksillä epigeneettisten säätelijöiden lysiinin spesifisen demetylaasientsyymin 4 (KDM4A, KDM4B, KDM4D) sekä sirtuiinien (SIRT1, SIRT4, SIRT6), hypoksiaa indusoivien tekijöiden (HIF-1α, HIF-2α), prolyylihydroksylaasientsyymien (PHD1, PHD2, PHD3) ja DNA:ta korjaavien proteiinien Rap1 vaikuttuvan tekijä 1 (Rif1) ja O6-metyyliguaniini-DNA metyylitransferaasin (MGMT) ilmentymistä edustavissa klassista Hodgkinin lymfoomaa sairastavien potilaiden (engl. cHL) näytteissä. Heikko 8-OHdG värjäytyminen ennusti ennenaikaista taudin uusiutumaa levinneessä HL:ssa ja korkea MnSOD ilmaantuvuus ennusti ennenaikaista taudin uusiutumaa koko HL -ryhmässä. Sädehoidetuilla cHL potilailla voimakas PHD1, KDM4B ja KDM4D värjäytyminen ennusti ennenaikaista taudin uusiutumaa. Tulokset osoittivat myös, että erityisesti sädehoidetuilla levinneen taudin cHL potilailla voimakas HIF-1α, SIRT6, Rif1 ja SIRT6 yhdessä Rif1:n kanssa oli yhteydessä pidentyneeseen uusiutumavapaaseen aikaan. Monimuuttuja-analyysissä PHD1, MnSOD, 8-OHdG ja Rif1 itsenäisenä ja yhdessä SIRT6 kanssa ennustivat tilastollisesti merkitsevästi taudin ennenaikaista uusiutumaa. Tulokset osoittavat näiden eri biomarkkereiden merkittävyyden HL:ssä, erityisesti sädehoitoa saaneilla potilailla. Tuloksista voi olla hyötyä, kun hoitokäytäntöjä yksilöidään, mikä voisi helpottaa välttämään liiallista hoitoa ja hallitsemaan pitkäaikaisiin hoitoihin liittyviä haittoja. Näiden alustavien havaintojen vahvistamiseksi tarvitaan kuitenkin lisätutkimuksia
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Prognostic markers"

1

CNS cancer: Models, markers, prognostic factors, targets, and therapeutic approaches. Central nervous system cancer: Humana Press, 2009.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Diagnostic and prognostic biomarkers and therapeutic targets in melanoma. Totowa, N.J: Humana, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
3

McNamara, M. Morphologic and molecular markers of prognosis in ocular melanoma. Dublin: University College Dublin, 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
4

Hughes, Mark D. Point-of-care testing: Status and prognosis. Waltham, MA: Decision Resources, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
5

Leckey, Joan Lesley. Urinary and tumour markers of disease recurrence and prognosis in transitional cell carcinoma of the bladder. [s.l: The Author], 1997.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
6

Giampietro, Gasparini, and Hayes Daniel 1951-, eds. Biomarkers in breast cancer: Molecular diagnostics for predicting and monitoring therapeutic effect. Totowa, N.J: Humana Press, 2006.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
7

International Falk Workshop (1995 Basel, Switzerland). Surrogate markers to assess efficacy of treatmentin chronic liver diseases: Proceedings of the International Falk Workshop held in Basel, Switzerland, October 23-24, 1995. Dordrecht: Kluwer Academic, 1996.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
8

Prognostic Markers in Hematologic Oncology. Informa Healthcare, 2005.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
9

New Prognostic and Predictive Markers in Cancer Progression. MDPI, 2021. http://dx.doi.org/10.3390/books978-3-03943-978-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Lau, Suzanne Kit-Yan. Validation of putative prognostic markers for non-small cell lung carcinoma. 2007.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Book chapters on the topic "Prognostic markers"

1

Bahler, David. "Prognostic Markers." In Molecular Pathology Library, 65–72. Boston, MA: Springer US, 2010. http://dx.doi.org/10.1007/978-1-4419-5698-9_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Schuh, Anna. "Prognostic Markers." In Hematologic Malignancies, 53–65. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-11392-6_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Sienko, Anna, Timothy Craig Allen, and Philip T. Cagle. "Prognostic Markers." In Molecular Pathology Library, 193–99. New York, NY: Springer New York, 2008. http://dx.doi.org/10.1007/978-0-387-72430-0_18.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rhodes, A., P. J. Newman, and E. D. Bennett. "Prognostic Markers in Sepsis." In Yearbook of Intensive Care and Emergency Medicine, 238–46. Berlin, Heidelberg: Springer Berlin Heidelberg, 1998. http://dx.doi.org/10.1007/978-3-642-72038-3_21.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Habuchi, Tomonori. "Prognostic Markers for Bladder Cancer." In Bladder Tumors:, 139–63. Totowa, NJ: Humana Press, 2010. http://dx.doi.org/10.1007/978-1-60761-928-4_8.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Garcia, Agustin A., and Nazish Ahmad. "Prognostic Markers in Breast Cancer." In Biomarkers in Oncology, 25–42. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-9755-5_2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Davies, Janine M., and Howard L. McLeod. "Prognostic Markers in Colon Cancer." In Biomarkers in Oncology, 131–62. New York, NY: Springer New York, 2012. http://dx.doi.org/10.1007/978-1-4419-9755-5_7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Selvi, Radhakrishna. "Breast Pathology: Conventional Prognostic Markers." In Breast Diseases, 229–31. New Delhi: Springer India, 2014. http://dx.doi.org/10.1007/978-81-322-2077-0_25.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Glimelius, Bengt. "Prognostic factors including clinical markers." In Cancer Treatment and Research, 89–96. Boston, MA: Springer US, 1989. http://dx.doi.org/10.1007/978-1-4613-1739-5_6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Christenson, Robert H., and Hassan M. E. Azzazy. "Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers." In Cardiac Markers, 59–86. Totowa, NJ: Humana Press, 2003. http://dx.doi.org/10.1007/978-1-59259-385-9_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Prognostic markers"

1

Pinho, Rafaela Seixas, Afonso Moraes Melo Junior, Rafael Silva Lemos, Amanda da Silva Furtado, and Luís Eduardo Werneck de Carvalho. "Gliomas: tumor markers and prognosis." In XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.538.

Full text
Abstract:
Background: Gliomas are classified based from the molecular parameters involved in their pathogenesis, which influence their prognosis. The parameters are based on the mutation of the genes encoding the enzyme isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), on the codelection of the arms of chromosome 1p/19q and the promoting hypermethylation of the MGMT gene. Objectives: identify tumor markers related to gliomas and their prognostic values. Methods: integrative review of the literature based on pubmed, lilacs and scielo platforms. Articles published in English, Portuguese and Spanish between 2016 and 2021 were included. Articles that were not related to the theme were excluded from the analysis. Results: The IDH1 and 2 genes are traditional markers and mutations in these genes are associated with a better prognosis. The codeletion 1p/19q, on the other hand, is indicative of a more favorable prognosis when related to tumors without codeletion. MGMT gene hypermethylation has strong prognostic value in patients treated with radiotherapy and chemotherapy with alkyl agentes, because the low expression of the MGMT gene allows better efficacy of the therapy, which would be prevented by the MGMT enzyme. The circulating marker microRNA – 221 (miRNA), obtained by less invasive techniques, is an indicator of poor prognosis, however, it has not yet obtained clinical validation for use. Conclusion: It is concluded that the tumor markers that indicate a better prognosis are the genes IDH-I and II, the codelection 1p / 19q and the hypermethylation of the MGMT gene. While miRNA showed a worse prognosis.
APA, Harvard, Vancouver, ISO, and other styles
2

"Rational Identification of Prognostic Markers of Breast Cancer." In International Conference on Bioinformatics Models, Methods and Algorithms. SCITEPRESS - Science and and Technology Publications, 2014. http://dx.doi.org/10.5220/0004915202650270.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Williams, Jennie L., and Ping Ji. "Abstract A54: miRNA profiling: prognostic markers in chemoprevention." In Abstracts: AACR International Conference on the Science of Cancer Health Disparities‐‐ Sep 30-Oct 3, 2010; Miami, FL. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1055-9965.disp-10-a54.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Roth, S., R. M'pembele, A. Stroda, C. Jansen, G. Lurati Buse, I. Tudorache, U. Boeken, et al. "New Prognostic Markers for Patients Undergoing VA-ECMO." In 51st Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG). Georg Thieme Verlag KG, 2022. http://dx.doi.org/10.1055/s-0042-1742846.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lima, Beatriz Alves, Andressa da Silva Pereira, Bruna Alves Lima, Diana Gonçalves Lima, Leonardo Ferreira Pucci, Renato Moraes Ferreira, Tiago Castro Ferreira, and Henrique Ferreira Pucci. "PREDICTORS OF BREAST CANCER PROGNOSIS BASED ON TUMOR BIOMARKERS." In Abstracts from the Brazilian Breast Cancer Symposium - BBCS 2021. Mastology, 2021. http://dx.doi.org/10.29289/259453942021v31s2022.

Full text
Abstract:
Objective: To analyze the tumor biological markers of breast cancer associated with the prognostic of the disease. Methodology: A systematic review was carried out on the Scielo, PubMed, and the National Cancer Institute databases on the topic. Descriptors used were: tumor biomarkers, breast cancer, and prognosis. Thus, 15 articles published between 2001 and 2020 were selected. Results: Breast cancer, characterized by the disordered multiplication of breast cells, is the most incident in women in the world, representing 24.2% of the total cases in 2018, and the most frequent cause of death in this gender. Accordingly, tumor markers are complementary tests for early diagnosis, since they are macromolecules derived from the tumor and biological fluids. The evaluation of tumor markers is of paramount importance due to the great diversity in clinical progression of breast cancer, for example, those hormone receptors (estrogen and progesterone), MIB-1, Ki-67, PCNA, p53, and c-erbB-2. Hence, about two-thirds of breast cancers are positive for hormone receptors and are related to a more favorable prognosis. PCNA (36 kDa protein perceptible in the cell nucleus from the late G1 to the S phase of the cell cycle) and MIB-1 (direct antibody against parts of the Ki-67 antigen) have a high proportion of tumor cells associated with a high-degree tumor differentiation, indicating a worse prognosis. Furthermore, mutations in the p53 and c-erbB-2 genes report low levels of estrogen and progesterone receptors, leading to a worse prognosis. Conclusion: In brief, the recognition of the main markers helps in the identification of patients with potentially aggressive tumors and in the mortality reduction of breast cancer, through treatments that can alter the course of the disease. On account of this, it is known that the tumor markers must be used in combination with the other methods such as diagnostic, prognostic, and therapeutic modifications.
APA, Harvard, Vancouver, ISO, and other styles
6

Foerster, Y., M. Diensthuber, S. Balster, J. Gabrielpillai, H. Petzold, J. Wagenblast, T. Stöver, and C. Geißler. "Neurotrophin receptors - prognostic markers and therapeutic targets for HNSCC?" In Abstract- und Posterband – 91. Jahresversammlung der Deutschen Gesellschaft für HNO-Heilkunde, Kopf- und Hals-Chirurgie e.V., Bonn – Welche Qualität macht den Unterschied. © Georg Thieme Verlag KG, 2020. http://dx.doi.org/10.1055/s-0040-1710952.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Geißler, C., Y. Foerster, M. Diensthuber, J. Wagenblast, S. Balster, J. Gabrielpillai, H. Petzold, and T. Stöver. "Neurotrophin receptors- prognostic markers and therapeutic targets for HNSCC?" In 100 JAHRE DGHNO-KHC: WO KOMMEN WIR HER? WO STEHEN WIR? WO GEHEN WIR HIN? Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1727956.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Achaiah, Andrew, Andrea Pereira, Harriet Bothwell, Kritica Dwivedi, Armila Rathnapala, Rosia Barker, Valentina Iotchkova, Rachel Hoyles, and Ling-Pei Ho. "Blood leukocyte levels as potential prognostic markers in IPF." In ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa388.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kujawa, Katarzyna A., Ewa Zembala-Nożyńska, Alexander J. Cortez, Jolanta Kupryjańczyk, and Katarzyna M. Lisowska. "423 Fibronectin and periostin as prognostic markers in ovarian cancer." In ESGO SoA 2020 Conference Abstracts. BMJ Publishing Group Ltd, 2020. http://dx.doi.org/10.1136/ijgc-2020-esgo.136.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Stetson, Lindsay C., Quinn T. Ostrom, Peter Liao, Andrew E. Sloan, Mark R. Chance, and Jill S. Barnholtz-Sloan. "Abstract 4220: Heterogeneous distribution of prognostic protein markers in glioblastoma." In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-4220.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Reports on the topic "Prognostic markers"

1

Lapointe, Jacques. Identification of Prostate Cancer Prognostic Markers. Fort Belvoir, VA: Defense Technical Information Center, October 2013. http://dx.doi.org/10.21236/ada595253.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Gullapalli, Rao P. Investigation of Prognostic Ability of Novel Imaging Markers for Traumatic Brain Injury (TBI). Fort Belvoir, VA: Defense Technical Information Center, October 2011. http://dx.doi.org/10.21236/ada577060.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Gilcrease, Michael Z. Investigation of Alpha6 Integrins and Their Signaling Intermediate as Prognostic Markers for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2002. http://dx.doi.org/10.21236/ada407363.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gilcrease, Michael Z. Investigation of Alpha6 Integrins and Their Signaling Intermediates as Prognostic Markers for Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, May 2004. http://dx.doi.org/10.21236/ada425749.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Keyomarsi, Khandan. Cyclin E, A Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 1998. http://dx.doi.org/10.21236/ada368551.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Keyomarsi, Khandan. Cyclin E, a Potential Prognostic Marker in Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, October 1997. http://dx.doi.org/10.21236/ada341275.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Baylin, Stephen B. Hypermethylation of AP-2Alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, May 2008. http://dx.doi.org/10.21236/ada494142.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Baylin, Stephen. Hypermethylation of AP-2alpha as a Prognostic Marker for DCIS. Fort Belvoir, VA: Defense Technical Information Center, May 2006. http://dx.doi.org/10.21236/ada456138.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Pettijohn, David. Oligosaccharide Markers for Prognosis of Low-Risk Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 1995. http://dx.doi.org/10.21236/ada306440.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pettijohn, David. Oligosaccharide Markers for Prognosis of Low-Risk Breast Cancer. Fort Belvoir, VA: Defense Technical Information Center, September 1999. http://dx.doi.org/10.21236/ada382780.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Prognostic markers' for particular source types:
Journal articles Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography